Anna Lundahl

417 total citations
18 papers, 316 citations indexed

About

Anna Lundahl is a scholar working on Pharmacology, Oncology and Surgery. According to data from OpenAlex, Anna Lundahl has authored 18 papers receiving a total of 316 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pharmacology, 10 papers in Oncology and 3 papers in Surgery. Recurrent topics in Anna Lundahl's work include Pharmacogenetics and Drug Metabolism (11 papers), Drug Transport and Resistance Mechanisms (10 papers) and Drug-Induced Hepatotoxicity and Protection (3 papers). Anna Lundahl is often cited by papers focused on Pharmacogenetics and Drug Metabolism (11 papers), Drug Transport and Resistance Mechanisms (10 papers) and Drug-Induced Hepatotoxicity and Protection (3 papers). Anna Lundahl collaborates with scholars based in Sweden, Finland and United States. Anna Lundahl's co-authors include Hans Lennernäs, Ulf Bondesson, Mikael Hedeland, Lars Knutson, J. A. Schrickx, Helena Thörn, Paul A. Dickinson, Kajsa P. Kanebratt, Scott A. Seaman and Johannes Wikström and has published in prestigious journals such as Scientific Reports, British Journal of Pharmacology and Clinical Pharmacology & Therapeutics.

In The Last Decade

Anna Lundahl

18 papers receiving 312 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anna Lundahl Sweden 10 106 101 83 39 30 18 316
Ann‐Charlotte Egnell Sweden 8 182 1.7× 96 1.0× 218 2.6× 25 0.6× 10 0.3× 11 474
Liling Liu United States 10 159 1.5× 80 0.8× 111 1.3× 24 0.6× 7 0.2× 15 348
Ling Huang China 13 86 0.8× 108 1.1× 184 2.2× 33 0.8× 26 0.9× 49 473
Muhammad Akram Pakistan 10 50 0.5× 26 0.3× 126 1.5× 35 0.9× 10 0.3× 27 319
Paresh P. Chothe United States 14 129 1.2× 299 3.0× 178 2.1× 28 0.7× 5 0.2× 34 571
Wafaa El-Sankary United Kingdom 6 290 2.7× 161 1.6× 129 1.6× 19 0.5× 7 0.2× 7 502
Yoon‐Jee Chae South Korea 11 28 0.3× 74 0.7× 90 1.1× 32 0.8× 3 0.1× 48 311
Xiaomin Deng China 11 232 2.2× 89 0.9× 100 1.2× 56 1.4× 5 0.2× 20 450
X.‐Y. Zhou China 10 90 0.8× 41 0.4× 84 1.0× 19 0.5× 2 0.1× 47 306
Yves Vandenberghe Belgium 15 290 2.7× 115 1.1× 271 3.3× 12 0.3× 16 0.5× 23 610

Countries citing papers authored by Anna Lundahl

Since Specialization
Citations

This map shows the geographic impact of Anna Lundahl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Lundahl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Lundahl more than expected).

Fields of papers citing papers by Anna Lundahl

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna Lundahl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Lundahl. The network helps show where Anna Lundahl may publish in the future.

Co-authorship network of co-authors of Anna Lundahl

This figure shows the co-authorship network connecting the top 25 collaborators of Anna Lundahl. A scholar is included among the top collaborators of Anna Lundahl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna Lundahl. Anna Lundahl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Lundahl, Anna, Rod Hughes, J.O. Almquist, et al.. (2025). AZD0449, an inhaled JAK1 inhibitor, in healthy participants and patients with mild asthma. British Journal of Clinical Pharmacology. 92(1). 257–268. 1 indexed citations
2.
Brightling, Christopher E., Marco Caminati, Jean‐Pierre Llanos, et al.. (2024). Biomarkers and clinical outcomes after tezepelumab cessation. Annals of Allergy Asthma & Immunology. 133(3). 310–317.e4. 7 indexed citations
3.
Lundahl, Anna, Jonathan Grigg, Gillian Hunter, et al.. (2024). Pharmacokinetics, pharmacodynamics and safety of tezepelumab in children with asthma. PA3562–PA3562. 1 indexed citations
4.
Huang, Yingbo, Weifeng Tang, Anna Lundahl, et al.. (2023). Understanding Statin‐Roxadustat Drug–Drug‐Disease Interaction Using Physiologically‐Based Pharmacokinetic Modeling. Clinical Pharmacology & Therapeutics. 114(4). 825–835. 9 indexed citations
5.
Lundahl, Anna, et al.. (2022). Does the choice of applied physiologically‐based pharmacokinetics platform matter? A case study on simvastatin disposition and drug–drug interaction. CPT Pharmacometrics & Systems Pharmacology. 11(9). 1194–1209. 12 indexed citations
6.
Almquist, J.O., S. Michaela Rikard, Maria Wågberg, et al.. (2020). Model‐Based Analysis Reveals a Sustained and Dose‐Dependent Acceleration of Wound Healing by VEGF‐A mRNA (AZD8601). CPT Pharmacometrics & Systems Pharmacology. 9(7). 384–394. 6 indexed citations
7.
Sun, Naidi, Bo Ning, Kenny M. Hansson, et al.. (2018). Modified VEGF-A mRNA induces sustained multifaceted microvascular response and accelerates diabetic wound healing. Scientific Reports. 8(1). 17509–17509. 86 indexed citations
8.
9.
Lundahl, Anna, et al.. (2018). Human hepatocytes and cytochrome P450‐selective inhibitors predict variability in human drug exposure more accurately than human recombinant P450s. British Journal of Pharmacology. 175(11). 2116–2129. 16 indexed citations
10.
Sundqvist, Monika, et al.. (2015). Quantifying and Communicating Uncertainty in Preclinical Human Dose‐Prediction. CPT Pharmacometrics & Systems Pharmacology. 4(4). 243–254. 8 indexed citations
11.
12.
Thörn, Helena, Anna Lundahl, J. A. Schrickx, Paul A. Dickinson, & Hans Lennernäs. (2011). Drug metabolism of CYP3A4, CYP2C9 and CYP2D6 substrates in pigs and humans. European Journal of Pharmaceutical Sciences. 43(3). 89–98. 51 indexed citations
13.
Lundahl, Anna, Mikael Hedeland, Ulf Bondesson, & Hans Lennernäs. (2011). In Vivo Investigation in Pigs of Intestinal Absorption, Hepatobiliary Disposition, and Metabolism of the 5α-Reductase Inhibitor Finasteride and the Effects of Coadministered Ketoconazole. Drug Metabolism and Disposition. 39(5). 847–857. 12 indexed citations
14.
Palm, Johan, et al.. (2010). Effects of Ketoconazole on the In Vivo Biotransformation and Hepatobiliary Transport of the Thrombin Inhibitor AZD0837 in Pigs. Drug Metabolism and Disposition. 39(2). 239–246. 7 indexed citations
15.
Lundahl, Anna. (2010). In vivo Pharmacokinetic Interactions of Finasteride and Identification of Novel Metabolites. KTH Publication Database DiVA (KTH Royal Institute of Technology). 1 indexed citations
16.
Lundahl, Anna, Hans Lennernäs, Lars Knutson, Ulf Bondesson, & Mikael Hedeland. (2009). Identification of Finasteride Metabolites in Human Bile and Urine by High-Performance Liquid Chromatography/Tandem Mass Spectrometry. Drug Metabolism and Disposition. 37(10). 2008–2017. 15 indexed citations
17.
Lundahl, Anna, et al.. (2009). Enterohepatic Disposition of Rosuvastatin in Pigs and the Impact of Concomitant Dosing with Cyclosporine and Gemfibrozil. Drug Metabolism and Disposition. 37(12). 2349–2358. 28 indexed citations
18.
Lundahl, Anna, Mikael Hedeland, Ulf Bondesson, Lars Knutson, & Hans Lennernäs. (2008). The effect of St. John's wort on the pharmacokinetics, metabolism and biliary excretion of finasteride and its metabolites in healthy men. European Journal of Pharmaceutical Sciences. 36(4-5). 433–443. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ann‐Charlotte Egnell Breakdown of academic impact, for papers by Liling Liu Breakdown of academic impact, for papers by Ling Huang Breakdown of academic impact, for papers by Muhammad Akram Breakdown of academic impact, for papers by Paresh P. Chothe Breakdown of academic impact, for papers by Wafaa El-Sankary Breakdown of academic impact, for papers by Yoon‐Jee Chae Breakdown of academic impact, for papers by Xiaomin Deng Breakdown of academic impact, for papers by X.‐Y. Zhou Breakdown of academic impact, for papers by Yves Vandenberghe
Rankless by CCL
2026